// App-Quantinova.ai

SAT-221 : CARDIO-RENAL-METABOLIC COMORBIDITIES AND ASSOCIATION WITH CARDIOVASCULAR OUTCOMES AND MORTALITY IN NEWLY DIAGNOSED PATIENTS WITH T2DM

Researchers

Presenter

  • D. Cherney

Principal Investigators

  • D. Wheeler

  • M. Kosiborod

  • S. Arnold

  • S. MacLachlan

  • P. Hunt

  • H. Chen

  • E. Repetto

  • J. Vora

Medical Centers

  • Real-world Evidence, Evidera, Waltham, MA

  • Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA

  • Diabetes and Endocrinology, Royal Liverpool University Hospital, Liverpool, United Kingdom

  • Real-World Evidence, Evidera, London, United Kingdom

  • University Health Network - Toronto Western Hospital, Toronto, ON, Canada

  • Department of Haematological Medicine, King's College London, London, United Kingdom

  • Cardiothoracic Surgery, Saint Luke's Mid America Heart Institute, Kansas City, MO

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Type 2 diabetes mellitus

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved